DDInter1042 DDInter485
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Daunorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
Daunorubicin {u} (Compound) binds {v} (Gene) CYP1A2
Daunorubicin {u} (Compound) upregulates {v} (Gene) GDI1
Daunorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Daunorubicin {u} (Compound) downregulates {v} (Gene) TAF5
Daunorubicin {u} (Compound) causes {v} (Side Effect) Sickness
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Daunorubicin (Compound) resembles Doxorubicin (Compound)
Daunorubicin (Compound) resembles Valrubicin (Compound)
Daunorubicin (Compound) treats hematologic cancer (Disease)
Daunorubicin (Compound) binds CYP1A2 (Gene)
Daunorubicin (Compound) upregulates GDI1 (Gene)
Daunorubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Daunorubicin (Compound) downregulates TAF5 (Gene)
Daunorubicin (Compound) causes Sickness (Side Effect)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin